Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Ibrutinib Related Intermediates: (S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1 4-Phenoxyphenylboronic Acid CAS 51067-38-0 Ibrutinib Intermediate N-2 CAS 330786-24-8 Ibrutinib Intermediate N-3 CAS 330792-70-6 Ibrutinib CAS 936563-96-1| Item | Specifications |
| Appearance | White Powder or Crystals |
| Chiral Purity | >99.5% (GC) |
| Chemical Purity | >99.5% (GC) |
| Water (K.F) | ≤0.50% |
| Methanol (GC) | ≤50ppm |
| Ethanol (GC) | ≤50ppm |
| DCM (GC) | ≤500ppm |
| 3-Hydroxypiperidine | ≤0.10% |
| 3-Hydroxypyridine | ≤0.20% |
| 1-Boc-3-Piperidone | ≤0.10% |
| 1-Boc-4-Hydroxypiperidine | ≤0.10% |
| 1.96 RRT | ≤0.20% |
| Any Unspecified Impurity | ≤0.10% |
| Test Standard | Enterprise Standard |
| Usage | Pharmaceutical Intermediates; Chiral Compounds |
Description:
Specifications:
Package & Storage:
| Chemical Name | (S)-1-Boc-3-Hydroxypiperidine |
| Synonyms | (S)-1-(tert-Butoxycarbonyl)-3-Hydroxypiperidine; (S)-1-Boc-3-Piperidinol |
| CAS Number | 143900-44-1 |
| CAT Number | RF-CC299 |
| Stock Status | In Stock, Production Capacity 20 Tons/Month |
| Molecular Formula | C10H19NO3 |
| Molecular Weight | 201.27 |
| Melting Point | 52.0~56.0℃ |
| Solubility | Soluble in Methanol |
| Specific Rotation [a]20/D | +9.0°~+11.0° (C=1 in Chloroform) |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
(S)-1-Boc-3-Hydroxypiperidine (CAS: 143900-44-1) is an important chiral intermediate for the synthesis of Ibrutinib (CAS: 936563-96-1). Ibrutinib is a kind of Bruton tyrosine kinase (BTK) inhibitor, it could be used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). MCL and CLL are belonged to the B-cell non-Hodgkin's lymphoma, which is difficult to cure and easy to recurrent. Common chemical immunotherapy does not have the targeting, often occurs 3 or 4 adverse reactions. Ibrutinib and B lymphocytes could target with BTK which is necessary for formation, differentiation, and transmission of information, inhibit BTK activity irreversibly, and inhibit tumor cell proliferation and survival effectively. Ibrutinib could be rapidly absorbed after oral administration, during 1~2h reach maximum blood concentration, adverse reactions belong to one or two, therefore, Ibrutinib will become a new choice of treatment of CLL and MCL.
